Compare AbbVie Inc (ABBV) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Lululemon Athletica Inc — how do they compare? AbbVie Inc trades at $253.44 (market cap $449.91B), while Lululemon Athletica Inc trades at $113.3 (market cap $13.13B). The key difference: AbbVie Inc is far larger — about 34.3× Lululemon Athletica Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Lululemon Athletica Inc pays none. Which is the better fit depends on your goals.
| ABBV | LULU | |
|---|---|---|
Market Cap | $449.91B | $13.13B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $238.54 |
52-Week Low | $184.85 | $105.43 |
Enterprise Value | $513.38B | $13.75B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
LULU trades at $115.07, down 2.84% for the day, reflecting recent bearish sentiment amid a 45% year-to-date decline. The stock is near its pivot point of $115, with technical indicators signaling a bearish trend. Fundamentally, the company reported strong revenue of $10.59B in 2025 and a net income margin of 17.13%, with a low P/E of 9.36 suggesting undervaluation. Recent news highlights board settlement with founder Chip Wilson but also cultural missteps in China and a class-action lawsuit over tariff costs.
The outlook is mixed: attractive valuation and international growth potential contrast with North American weakness and brand reputation risks. Analyst consensus is a $130.53 price target with 41% buy ratings, but near-term volatility persists. Key risks include execution on guidance, competitive pressures, and macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
